CVS pushes further into generic drugs with Sandoz partnership for new discount Humira

CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.